Clayton Bossier
Family · Cut Off, LANPI 1730128166
Payments from drug & device makers
Across 185 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$720
- Novo Nordisk$522
- GSK$339
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$296
- Gilead$262
- AstraZeneca$207
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,025100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $720 |
| Novo Nordisk | 22 | $522 |
| GSK | 14 | $339 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $296 |
| Gilead | 3 | $262 |
| AstraZeneca | 11 | $207 |
| Lilly USA, LLC | 12 | $182 |
| Teva Pharmaceuticals USA, Inc. | 10 | $173 |
| Exact Sciences | 6 | $126 |
| Merck | 2 | $126 |
| Phathom Pharmaceuticals, Inc. | 3 | $125 |
| Biohaven Pharmaceuticals, Inc. | 5 | $117 |
| Vanda Pharmaceuticals Inc. | 5 | $112 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $107 |
| Pfizer | 7 | $106 |
| Astellas Pharma US Inc | 5 | $88 |
| Alkermes, Inc. | 2 | $73 |
| Medtronic | 1 | $70 |
| Amgen | 3 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $44 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Boehringer Ingelheim | 2 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Bayer | 1 | $18 |
| Braeburn Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Eisai Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,025 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 182 | $191,127 |
| Teriflunomide | 12 | $74,748 |
| JardianceEmpagliflozin | 53 | $54,577 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $50,899 |
| TrulicityDulaglutide | 43 | $43,572 |
| EliquisApixaban | 38 | $33,360 |
| OzempicSemaglutide | 17 | $25,120 |
| FarxigaDapagliflozin Propanediol | 30 | $21,315 |
| VraylarCariprazine Hcl | 13 | $19,965 |
| TradjentaLinagliptin | 19 | $19,317 |
| LinzessLinaclotide | 27 | $18,041 |
| CaplytaLumateperone Tosylate | 11 | $17,575 |
| Nurtec OdtRimegepant Sulfate | 13 | $15,481 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $15,367 |
| MyrbetriqMirabegron | 14 | $9,977 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $182 | $234,699225 claims |
| Boehringer IngelheimJardiance, Tradjenta | $25 | $73,89472 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $339 | $58,98671 claims |
| PfizerEliquis, Nurtec Odt | $106 | $48,84051 claims |
| AbbVieVraylar, Linzess | $720 | $38,00640 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $207 | $36,68253 claims |
| Novo NordiskOzempic | $522 | $25,12017 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $296 | $17,57511 claims |
| MerckJanumet, Belsomra | $126 | $16,32733 claims |
| Astellas Pharma US IncMyrbetriq | $88 | $9,97714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.
Other family in Cut Off
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.